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Abstract The p53-binding protein 2 (53BP2) was identified as a
binding protein to a tumor suppressor p53. We examined the
genetic aberrations of 53BP2 gene in various human cancer cell
lines. Although no gross genomic alteration or mutation of
53BP2 gene was observed, 53BP2 mRNA levels were highly
variable. There was no association between the 53BP2 mRNA
level and the p53 status. When we examined sensitivities of these
cell lines to DNA-damaging agents including UV irradiation, X-
ray irradiation and cis-diamine-dichloroplatinum (CDDP), we
found that higher 53BP2 mRNA expression was correlated with
the sensitivity to these agents.
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1. Introduction
The p53-binding protein 2 (53BP2) has been initially iden-
ti¢ed by its ability to bind the core domain of p53 tumor
suppressor gene product [1]. The binding of 53BP2 to wild-
type p53 but not some mutant forms of p53 suggested that
some of the biological functions of p53 wild-type protein, such
as induction of apoptosis and cell cycle arrest, might be medi-
ated by its interaction with 53BP2 [2^5].
The 53BP2 protein consists of 1005 amino acids with an K-
helical region, proline-rich (PXXP) region, ankyrin repeats
and Src-homology 3 (SH3) domain [1]. These PXXP and
SH3 structural motifs were found in various regulatory pro-
teins and appeared to be involved in protein-protein interac-
tions [2,6]. In fact, 53BP2 has been shown to bind a number
of proteins other than p53, such as Bcl-2 [4], protein phos-
phatase 1 [7] and the p65 subunit of nuclear factor UB (NF-
UB) [8] through the ankyrin repeats and SH3 domain of
53BP2. Recent crystallographic analysis has provided a struc-
tural basis for p53-53BP2 interaction and demonstrated that
the 53BP2-binding site on the p53 core domain consists of
evolutionarily conserved regions that are frequently mutated
in cancer and that it overlaps the site of DNA-binding [3].
Moreover, we have recently demonstrated that overexpression
of 53BP2 induced apoptosis and that NF-UB p65 subunit
bound to 53BP2 following the inhibition of the 53BP2-in-
duced apoptosis [8].
In cancer cells, mutations in p53 gene are the most common
genetic change in human cancer. It has been reported that
about half of human cancers have mutant p53 and the rest
of cancers possess wild-type p53 [9^11]. In this paper, we ¢rst
examined the possibility that those cancer cell lines with wild-
type p53 may have a mutation in 53BP2. However, no gross
genomic alteration or point mutation of the functional do-
mains of 53BP2 was detected. Thus, we also examined the
mRNA levels of 53BP2 in various cell lines and found the
correlation between the 53BP2 mRNA level and the sensitivity
to DNA-damaging agents.
2. Materials and methods
2.1. Cell lines
Cancer cell lines from various tissues including lung (NCI H460,
A549, SBC3, SBC5 and Lu99), breast (MCF7), colon (LoVo, SW480,
SW620, HT29 and DLD1) and leukocytes (MOLT4, CEM and
THP1) were examined. NCI H460, LoVo, MCF7, HT29, SW620,
MOLT4, CEM and THP1 were obtained from American Type Cul-
ture Collection (Rockville, MD, USA). A549, Lu99, SBC3 and SBC5
were obtained from Health Science Research Resources Bank (Osaka,
Japan). DLD1 and SW480 were obtained from Cell Resource Center
for Biomedical Research, Institute of Development, Aging and Can-
cer, Tohoku University (Sendai, Japan). A549, SBC3, MCF7 and
SBC5 were maintained in minimum essential medium (Gibco BRL,
Grand Island, NY, USA) supplemented with 10% heat-inactivated
fetal bovine serum. NCI H460, Lu99, HT29 and DLD1 were main-
tained in RPMI 1620 (Iwaki, Tokyo, Japan) with supplements de-
scribed above. SW620 and SW480 were maintained in Leibovitz’s
L-15 medium (Gibco BRL) and LoVo were maintained in Ham’s
F12 medium (Nissui, Tokyo, Japan) with above supplements. Cells
were grown at 37‡C in a humidi¢ed 5% CO2 incubator.
2.2. Southern and Northern blotting
Genomic DNA samples were prepared from each cell line by pro-
teinase K digestion and phenol-chloroform extraction as described
[12]. 10 Wg of each DNA sample was digested with either EcoRI or
HindIII, fractionated on a 0.7% agarose gel electrophoresis, and trans-
ferred to a nylon membrane (Hybond N; Amersham, Arlington
Heights, IL, USA). These membranes were cross-linked under ultra-
violet (UV) light. They were incubated in Hybrizol I (Oncor, Perry
Parkways, Gaithersburg, MD, USA) for 1 h at 42‡C and hybridized
at 42‡C overnight with [K-32P]dATP-labeled full-length 53BP2 cDNA
as a probe.
In order to examine 53BP2 mRNA levels, total RNA samples from
cell lines described above were prepared by using Trizol (Gibco BRL).
20 Wg of total RNA was fractionated by electrophoresis on a 1.0%
agarose gel containing 1UMOPS and 6.7% formaldehyde, transferred
to Hybond N membrane (Amersham) in 10Usaline sodium citrate
(SSC), and were covalently linked by 1200 J/m2 of UV light radiation.
Hybridization was performed in Hybrizol I (Oncor) at 42‡C overnight
with the [K-32P]dATP-labeled 53BP2 cDNA probe or glyceraldehyde
3-phosphate dehydrogenase (GAPDH) cDNA (internal control). The
¢nal wash was carried out in 0.1USSC and 0.1% sodium dodecyl
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sulfate at 65‡C for 20 min. For quantitation of 53BP2 mRNA and
that of GAPDH (as an internal control) in Northern blot, we used
Fuji BAS 2500 image analyzer (Fuji¢lm, Tokyo, Japan) [13]. The
relative ratio of 53BP2 mRNA level over GAPDH mRNA was calcu-
lated to compare the 53BP2 mRNA level of each cell line.
2.3. Nucleotide sequencing
The 53BP2 cDNA fragment, containing the proline-rich region,
ankyrin repeats and SH3 domain, was ampli¢ed by reverse transcrip-
tase-PCR (RT-PCR) with Titan One Tube RT-PCR system kit (Boeh-
ringer Mannheim, Mannheim, Germany). The following primer pairs
were used for RT-PCR reactions: primer pair 1 (spanning 2202^2425
nucleotides), 5P-TGTGCTTGATGTGTACCTGGAGG-3P and 5P-
CTAGCAGTAAAGCAAGGGGGTT-3P ; primer pair 2 (spanning
2369^3022 nucleotides), 5P-CAGAGCGTATCGCTCAT-3P and 5P-
AGTTTCAGGCCAAGCTC-3P (Fig. 1). RT-PCR reactions were per-
formed with approximately 1 Wg of total RNA prepared from each
cell line in 50 Wl reactions under the following conditions: reverse
transcription at 50‡C for 30 min; followed by 10 ampli¢cation cycles
consisting of denaturation at 94‡C for 1 min, annealing at 60‡C for
1 min and extension at 68‡C for 1 min and additional 25 ampli¢cation
cycles consisting of denaturation at 98‡C for 1 min, annealing at 60‡C
for 1 min, extension at 68‡C for 1 min with increment for 5 s to each
cycle at 68‡C and ¢nal extension at 68‡C for 7 min. The ampli¢ed
products were puri¢ed with phenol-chloroform extraction and ethanol
precipitation. The ampli¢ed DNA fragment was cloned into pCR
Blunt vector plasmid (Invitrogen, San Diego, CA, USA) according
to the manufacturer’s recommendations. Dideoxynucleotide sequenc-
ing reactions using ABI PRISM Dye Terminator Cycle Sequencing
Ready Reaction kit (Perkin-Elmer, Foster City, CA, USA) were per-
formed for sequence analysis on ABI PRISM 310 Genetic Analyzer
(Perkin-Elmer) according to the manufacturer’s recommendations.
2.4. UV irradiation, X-ray irradiation and cis-diamine-dichloroplatinum
(CDDP) treatment, and sensitivity or viability analysis
Cancer cell lines were cultured in six-well plates and incubated for
24 h until they reached half-con£uent. These cells were exposed to
UV-C (254 nm) or X-ray irradiation (M80-WE; Softex, Tokyo Japan)
at various doses, and incubated for an additional 46 h. In order to
determine the sensitivity to CDDP (Sigma, St. Louis, MO, USA), cells
were similarly cultured, incubated with CDDP at various concentra-
tions and incubated for an additional 48 h. The cell viability was
Fig. 1. Schematic diagram of 53BP2 protein and location of PCR primers used in this study. 53BP2 consists of 1005 amino acids with an
K-helical region, proline-rich region, ankyrin repeats and SH3 domain. The primer sets 1 and 2 correspond to the PXXP region and to the an-
kyrin repeats and SH3 domain, respectively. The regions responsible for the interaction with other proteins are indicated.
Table 1
Results of 53BP2 cDNA sequencing in various tumor cell lines
Cell line Tissue derived Pathologya p53 statusb 53BP2 sequencesc
Primer pair 1 Primer pair 2
A549 Lung ACC wt N N
NCI H460 Lung LCC wt N N
Lu99 Lung LCC wt N N
SBC3 Lung SCLC wt N N
SBC5 Lung SCLC R248L N N
MCF7 Breast ACC wt N N
LoVo Colon ACC wt N N
SW620 Colon ACC R273H N N
SW480 Colon ACC R273H/P309S N N
DLD1 Colon ACC S241F N N
HT29 Colon ACC R273H N N
MOLT4 Blood T cell ALL wt N N
CEM Blood T cell ALL R175H/R248H N N
THP1 Blood AMoL 174del 26 N N
aAbbreviations for pathological classi¢cation. LCC, large cell carcinoma; GCC, giant cell carcinoma; SCLC, small cell lung carcinoma; ACC,
adenocarcinoma.
bThe p53 status of each cell line was according to Jia et al. [19]. Mutant types including substitutions and deletions are described. ‘wt’, wild-
type.
cThe nucleotide sequence was determined with at least ¢ve independent clones for each preparation. N, no mutation.
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determined by sodium 3P-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay.
The cell viability was quanti¢ed by adding XTT dye to the cultures
and allowing it to be reacted upon for 3 h by the mitochondrial
dehydrogenases generated by viable cells. Absorbance was measured
at 450/690 nm. All the measurements were performed in more than
triplicates.
3. Results
3.1. Analysis of 53BP2 genome in human tumor cell lines
The genomic DNA was isolated from various tumor cell
lines and digested with restriction enzymes, HindIII or EcoRI
for Southern blotting hybridization. These cell lines included
¢ve from lung cancer (two from small cell lung cancer, two
from large cell carcinoma and one from adenocarcinoma), ¢ve
from colon adenocarcinoma and one from breast adenocarci-
noma. As demonstrated in Fig. 2, no gross alteration of
53BP2 gene was observed in these cell lines irrespective of
the status of p53 gene (either wild-type or mutant). Upon
EcoRI digestion, A549 and DLD1 revealed an aberrant
band of 8.1 kb, which is considered to be a polymorphism
since no alteration was detected with other digestions. We also
examined three human leukemia cell lines including MOLT4,
CEM and THP1, and detected no gross mutation in 53BP2
gene (data not shown).
3.2. 53BP2 cDNA sequencing
We have then determined the nucleotide sequences of the
53BP2 cDNA regions which are known to be involved in the
interaction with other proteins. Thus the 53BP2 cDNA frag-
ments corresponding to the PXXP motif (using primer set 1;
Fig. 1) and to the ankyrin repeats and SH3 domain (primer
set 2) were ampli¢ed from various tumor cell lines, cloned into
a vector, and subjected to the sequencing analysis. Although
we analyzed at least ¢ve independent clones from each set of
sample, no substitution, deletion or insertion was detected
among 14 cell lines tested (more than 140 cDNA clones
were examined) (Table 1). It was noted that even in seven
cell lines with wild-type p53 alleles, there was no mutation
in these regions of 53BP2 cDNA.
3.3. Expression of 53BP2 mRNA in tumor cell lines
Northern blotting analysis was performed with these cell
lines using full-length 53BP2 cDNA as a probe. The expected
4.5 kb band corresponding to 53BP2 mRNA was detected
from all the samples examined (Fig. 3). However, the amounts
of 53BP2 mRNA were variable among these cell lines. Thus,
we compared the level of 53BP2 mRNA with regard to the
GAPDH mRNA level in each cell line. There was no associ-
ation between the p53 status and the 53BP2 mRNA level
among these cell lines. However, regardless of the p53 status
(either wild-type or mutant), two cell lines (SBC3 and SBC5)
from small cell lung cancer showed a relatively high expres-
sion level. Another cell line (Lu99) from lung giant cell carci-
noma also had a relatively high level of 53BP2 mRNA ex-
pression. Since it is known that small cell lung cancer tends to
be highly sensitive to anti-cancer agents and irradiation [14^
16], we then examined the sensitivity of these cell lines to
various DNA-damaging agents.
Fig. 2. Southern blot analysis of the 53BP2 gene in human tumor cell lines. Approximately 10 Wg of the genomic DNA was restricted with
EcoRI or HindIII, electrophoresed in a 0.7% agarose gel, transferred to a nylon membrane and hybridized with the [K-32P]ATP-labeled human
53BP2 cDNA probe. A549 and DLD1 revealed an aberrant polymorphic band upon EcoRI digestion (arrow heads). The low densities of
53BP2 bands in HT29 (EcoRI) are due to the loss of DNA during the experimental procedure.
Fig. 3. Northern blot analysis of total RNA probed with 53BP2
cDNA (upper panel) and GAPDH (lower panel). Total RNA (20
Wg) was loaded onto each lane. 53BP2 mRNA levels represent the
relative amount of the 53BP2 mRNA normalized to that of
GAPDH mRNA. The mRNA levels were quanti¢ed by a Fuji BAS
2500 image analyzer.
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3.4. Sensitivity to UV, X-ray irradiation and CDDP
We examined ¢ve cell lines, including three (SBC3, SBC5
and Lu99) expressing high levels of 53BP2 mRNA and two
(A549 and NCI H460) expressing low levels of 53BP2 mRNA.
These cells were exposed to UV-C, X-ray irradiation, or treat-
ment with CDDP. The cell viability was measured by XTT
assay. As demonstrated in Fig. 4A, the cells expressing high
levels of 53BP2 mRNA showed higher sensitivity to UV-C.
Similarly, these cell lines are relatively sensitive to X-ray irra-
diation although to a lesser extent (Fig. 4B). In contrast, A549
and NCI H460 were relatively resistant to UV-C and X-ray
irradiation. Upon treatment with CDDP, only SBC3 appeared
to be sensitive to the DNA damage-induced cell death.
Although we do not currently know the reason why other
cell lines expressing high levels of 53BP2 mRNA were resis-
tant to CDDP, additional mechanisms such as acquisition of
multiple drug resistance phenotype may have been involved.
4. Discussion
In this study, we have demonstrated the lack of genetic
abnormality of 53BP2 in various tumor cell lines irrespective
of the genetic status of p53. Thus, it is indicated that the
genetic abnormality of 53BP2 per se is not implicated in car-
cinogenesis, which is consistent with our previous results of
the chromosomal mapping of 53BP2 gene that was mapped at
1q42.1 and did not correlate with any genetic marker for the
susceptibility of hereditary cancers [17]. However, we also
found that 53BP2 mRNA is abundantly expressed in some
cell lines, which are relatively sensitive to various DNA-dam-
aging reagents.
Biological activities of 53BP2 have been implicated in pre-
vious studies. Iwabuchi et al. [1] initially reported that 53BP2
bound to the wild-type p53 but not to its mutant form and
recently that 53BP2 might be involved in augmentation of the
transcriptional activity of p53 thus reducing the oncogene-
mediated transformation [5]. Additionally, Naumovski and
Cleary et al. [4] demonstrated that Bcl-2 interacted with p53
with higher a⁄nity and that overexpression of 53BP2 induced
cell growth arrest and suggested that one of the actions of Bcl-
2 might be through interfering the 53BP2-binding to p53.
More importantly, we have recently demonstrated that
53BP2 induced apoptosis, when overexpressed, and that the
p65 subunit of NF-UB could block the 53BP2-induced apop-
tosis by directly interacting with 53BP2. These observations
that 53BP2 could interact with p53 as well as Bcl-2 and p65
may indicate that various biological actions of these proteins
may be regulated by 53BP2. Since p53, Bcl-2 and p65 are
important regulatory factors involved in stress response, cell
growth and apoptosis, functional interactions among these
proteins may determine the direction of cellular responses.
We found that 53BP2 mRNA levels were diverse among
various cell lines and there was no association between the
53BP2 mRNA level and the p53 status. The mRNA levels of
53BP2 of SBC3, SBC5 and Lu99 were relatively higher than
other lung cancer cell lines. SBC3 and SBC5 were derived
from small cell lung cancer, which is known highly sensitive
to anti-cancer agents and irradiation [14^16]. We thus exam-
ined the sensitivity of these cell lines to various DNA-damag-
ing agents and found that these cell lines were sensitive to UV
and X-ray irradiation. In contrast, cell lines with lower 53BP2
mRNA levels such as A549 and NCI H460 were resistant to
the cell death induced by these reagents. The lack of sensitiv-
ity of SBC5 and Lu99 to CDDP may possibly be ascribed to
other factors involved in the cellular sensitivity to anti-cancer
reagents such as P-glycoprotein, topoisomerase II and O-6-
alkylguanine-DNA-alkyltransferase, although this possibility
should be further substantiated [18]. In addition, p53 muta-
tion (in case of SBC5) might be involved in sensitivity to anti-
cancer agents [9,19]. These observations suggested a possibil-
ity that expression of 53BP2 might be correlated with the
sensitivity to DNA damage agents. Further studies are needed
to con¢rm this possibility by, for example, downregulating the
53BP2 mRNA by somatic gene targeting or transduction of
anti-sense 53BP2 mRNA. It is also interesting to explore
whether 53BP2 interacts with other members of the p53 fam-
ily such as p73 [20] and p51/p73L/p63 [21^23] since these
proteins share the similar DNA-binding motif that is known
to be involved in the interaction with 53BP2 as well.
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